Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar
PMC(0)


Article History
Submitted: 30 May 2013
Revised: 24 Jul 2013
First published online: 23 Dec 2013

Article Access Statistics
Abstract Page Views: 286
PDF Downloads: 148
Full Text Views: 0

Adv Pharm Bull. 2014;4(1):43-47 doi: 10.5681/apb.2014.007
PMID:24409408        PMCID:PMC3885367

Aberrant Phenotype in Iranian Patients with Acute Myeloid Leukemia

Original Research

Mehdi Jahedi 1, Karim Shamsasenjan 2, Zohreh Sanaat 1, Mohammad Reza Aliparasti 1,3,4, Shohreh Almasi 1,3,4, Mozhdeh Mohamadian 1, Babak Nejati 1, Amir Kamalifar 5, Ali Akbar Movassaghpour 1 *

1 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract
Purpose: The aim of this study was to evaluate the incidence of aberrant phenotypes and possible prognostic value in peripheral and bone marrow blood mononuclear cells of Iranian patients with AML. Methods: 56 cases of de novo AML (2010-2012) diagnosed by using an acute panel of monoclonal antibodies by multiparametric flowcytometry. Immunophenotyping was done on fresh bone marrow aspirate and/or peripheral blood samples using the acute panel of MoAbs is stained with Phycoerythrin (PE) /fluorescein isothiocyanate (FITC), Allophycocyanin (APC) and Peridinin-chlorophyll protein complex (perCP). We investigated Co-expression of lymphoid-associated markers CD2, CD3, CD7, CD 10, CD19, CD20 and CD22 in myeloblasts. Results: Out of the 56 cases, 32 (57.1%) showed AP. CD7 was positive in 72.7% of cases in M1 and 28.5% in M2 but M3 and M4 cases lacked this marker. We detected CD2 in 58.35 of M1cases, 21.40% of M2 cases, 33.3 of M3 and 20% of M5; but M4 patients lacked this marker. The CBC analysis demonstrated a wide range of haemoglobin concentration, Platelet and WBC count which varied from normal to anaemia, thrombocytopenia to thrombocytosis and leukopenia to hyper leukocytosis. Conclusions: Our findings showed that CD7 and CD2 were the most common aberrant marker in Iranian patients with AML. However, we are not find any significant correlation between aberrant phenotype changing and MRD in our population. Taken together, this findings help to provide new insights in to the investigation of other aberrant phenotypes that may play roles in diagnosis and therapeutic of AML.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Jahedi M
Articles by Shamsasenjan K
Articles by Sanaat Z
Articles by Aliparasti MR
Articles by Almasi S
Articles by Mohamadian M
Articles by Nejati B
Articles by Kamalifar A
Articles by Movassaghpour AA

PubMed
Articles by Jahedi M
Articles by Shamsasenjan K
Articles by Sanaat Z
Articles by Aliparasti MR
Articles by Almasi S
Articles by Mohamadian M
Articles by Nejati B
Articles by Kamalifar A
Articles by Movassaghpour AA

Similar articles in PubMed

Share this article!

Press Manuscript Online. Powered by MAADRAYAN